Negara: Kanada
Bahasa: Inggris
Sumber: Health Canada
HYDROCORTISONE
PFIZER CANADA ULC
H02AB09
HYDROCORTISONE
10MG
TABLET
HYDROCORTISONE 10MG
ORAL
100
Prescription
ADRENALS
Active ingredient group (AIG) number: 0106344002; AHFS:
APPROVED
2003-09-09
_CORTEF (hydrocortisone) _ _Page 1 of 32 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR CORTEF Hydrocortisone Tablets Tablet, 10 mg, 20 mg, Oral The Anatomical Therapeutic Chemical (ATC) Code: D07XA01 Corticosteroid USP Pfizer Canada ULC 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Date of Initial Authorization: December 31, 1954 Distributed by: TM Pharmacia Enterprises Sarl. Pfizer Canada ULC, licensee © Pfizer Canada ULC, 2023 Date of Revision: September 18, 2023 Submission Control Number: 274963 _ _ _CORTEF (hydrocortisone) _ _Page 2 of 32 _ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Other 09/2023 8 ADVERSE REACTIONS, 8.1 Adverse Reactions Overview 09/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ............................................................................................................. 4 1.1 Pediatrics .................................................................................................................. 5 1.2 Geriatrics .................................................................................................................. 5 2 CONTRAINDICATIONS ................................................................................................ 5 4 DOSAGE AND ADMINISTRATION ................................................................................ 5 4.1 Dosing Considerations ............................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ........................................................ 6 5 OVERDOSAGE ............. Baca dokumen lengkapnya